Availability of new fluorinated quinolones offers, in the hospital setting, the opportunity to change, in many circumstances, parenteral therapy with oral administration of drugs. This possibility must always depend upon medical considerations, but permits a cost-containment policy with a drastic reduction of hospitalization and therapeutic costs. As far as the latter is concerned a daily cost reduction of 70000-16000 lire is foreseeable.